Skip to main content

Table 5 Radioimmunotherapy for recurrent SCCHN receiving re-RT

From: Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience

Re-RT (21 pts, 1 pt treated for bone metastases)    
IMRT 16/22 pts    
3D-RT 3/22 pts    
conventional RT 3/22 pts    
prior RT Dose (Gy) time between RT treatments (months) cumulative Dose (Gy)
  median 66 83,5 106,4
  min 40 17 96
  max 70,4 293 125,6
Re-RT     
  median 45   
  min 34,2   
  max 59,6   
response (21 pts)    
CR 2 pts   
PR 10 pts   
SD 2 pts   
PD 5 pts   
dna 1 pt   
f/u unavailable 1 pt